CUE Cue Biopharma Inc

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit being held virtually from December 5-6, 2023.

During the fireside chat, Cue Biopharma will discuss recent data highlights from its lead clinical programs, CUE-101 and CUE-102, representative of the IL-2-based CUE-100 series of selective T cell engagers, as well as market opportunities, competitive positioning and anticipated milestones for 2024.

Presentation Details

JMP Securities Hematology and Oncology Summit

Date and Time: Tuesday, December 5, 11:30 a.m. EST

Webcast Link:

Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma

A live and archived webcast of the fireside chat will be available on the Events page in the Investors and Media section of the Company’s website at . The webcast will be archived for 30 days.

About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the body’s intrinsic immune system as T cell engagers without the need for ex vivo manipulation or broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit  and follow us on  and .

Investor Contact

Marie Campinell 

Senior Director, Corporate Communications

Cue Biopharma, Inc.

Media Contact

Maya Romanchuck

LifeSci Communications

 



EN
22/11/2023

Underlying

CUECue Biopharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cue Biopharma Inc

 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of ...

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, announced today the initiation of an investigator sponsored trial (IST) in rGBM at the DFCI with t...

August 13, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent...

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights Received FDA feedback on Pre-IND Briefing Document reinforcing Company’s intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease. Announced strategic research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases. Upfront payment of $12 million and ~$345 million in potential milesto...

August 12, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall ...

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients with low CPS (1-19)12-month overall survival of 88% and median overall survival (mOS) of 32 months BOSTON, July 16, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company de...

July 16, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, C...

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC12-month landmark survival of 88% and mOS of 32 months BOSTON, July 01, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided an update on its most advanc...

July 1, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinf...

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 BOSTON, June 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment o...

June 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch